Cytomegalovirus vaccines under clinical development
Congenital cytomegalovirus (CMV) infection is the most common infectious cause of disability in newborn infants. CMV also causes serious disease in solid organ (SOT) and haematopoietic stem cell transplant (HSCT) recipients. In otherwise healthy children and adults, primary CMV infection rarely caus...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-10-01
|
Series: | Journal of Virus Eradication |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2055664020308724 |
id |
doaj-a298e7aafe5647c8b4a9163971fd97b7 |
---|---|
record_format |
Article |
spelling |
doaj-a298e7aafe5647c8b4a9163971fd97b72021-05-04T07:23:55ZengElsevierJournal of Virus Eradication2055-66402016-10-0124198207Cytomegalovirus vaccines under clinical developmentMark R. Schleiss0Corresponding author: Mark R Schleiss, Department of Pediatrics, University of Minnesota Medical School, Division of Pediatric Infectious Diseases and Immunology, Center for Infectious Diseases and Microbiology Translational Research, 2001 6th Street SE, Minneapolis, MN, 55455, USA; Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USACongenital cytomegalovirus (CMV) infection is the most common infectious cause of disability in newborn infants. CMV also causes serious disease in solid organ (SOT) and haematopoietic stem cell transplant (HSCT) recipients. In otherwise healthy children and adults, primary CMV infection rarely causes illness. However, even asymptomatic CMV infections may predispose an individual towards an increased risk of atherosclerosis, cancer and immune senescence over the life course, although such associations remain controversial. Thus, although a vaccine against congenital CMV infection would have the greatest public health impact and cost-effectiveness, arguably all populations could benefit from an effective immunisation against this virus. Currently there are no licensed CMV vaccines, but there is increased interest in developing and testing potential candidates, driven by the demonstration that a recombinant CMV glycoprotein B (gB) vaccine has some efficacy in prevention of infection in young women and adolescents, and in CMV-seronegative SOT recipients. In this review, the recent and current status of candidate CMV vaccines is discussed. Evolving concepts about proposed correlates of protective immunity in different target populations for CMV vaccination, and how these differences impact current clinical trials, are also reviewed.http://www.sciencedirect.com/science/article/pii/S2055664020308724CMVcytomegalovirusvaccinepentameric complexcongenital infectionplacenta |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mark R. Schleiss |
spellingShingle |
Mark R. Schleiss Cytomegalovirus vaccines under clinical development Journal of Virus Eradication CMV cytomegalovirus vaccine pentameric complex congenital infection placenta |
author_facet |
Mark R. Schleiss |
author_sort |
Mark R. Schleiss |
title |
Cytomegalovirus vaccines under clinical development |
title_short |
Cytomegalovirus vaccines under clinical development |
title_full |
Cytomegalovirus vaccines under clinical development |
title_fullStr |
Cytomegalovirus vaccines under clinical development |
title_full_unstemmed |
Cytomegalovirus vaccines under clinical development |
title_sort |
cytomegalovirus vaccines under clinical development |
publisher |
Elsevier |
series |
Journal of Virus Eradication |
issn |
2055-6640 |
publishDate |
2016-10-01 |
description |
Congenital cytomegalovirus (CMV) infection is the most common infectious cause of disability in newborn infants. CMV also causes serious disease in solid organ (SOT) and haematopoietic stem cell transplant (HSCT) recipients. In otherwise healthy children and adults, primary CMV infection rarely causes illness. However, even asymptomatic CMV infections may predispose an individual towards an increased risk of atherosclerosis, cancer and immune senescence over the life course, although such associations remain controversial. Thus, although a vaccine against congenital CMV infection would have the greatest public health impact and cost-effectiveness, arguably all populations could benefit from an effective immunisation against this virus. Currently there are no licensed CMV vaccines, but there is increased interest in developing and testing potential candidates, driven by the demonstration that a recombinant CMV glycoprotein B (gB) vaccine has some efficacy in prevention of infection in young women and adolescents, and in CMV-seronegative SOT recipients. In this review, the recent and current status of candidate CMV vaccines is discussed. Evolving concepts about proposed correlates of protective immunity in different target populations for CMV vaccination, and how these differences impact current clinical trials, are also reviewed. |
topic |
CMV cytomegalovirus vaccine pentameric complex congenital infection placenta |
url |
http://www.sciencedirect.com/science/article/pii/S2055664020308724 |
work_keys_str_mv |
AT markrschleiss cytomegalovirusvaccinesunderclinicaldevelopment |
_version_ |
1721480007863238656 |